Shockwave Medical, Inc. SWAV recently announced that the researchers provided interim long-term follow-up results of up to three years, along with six-month data from the entire population of the ...
SANTA CLARA, Calif., April 08, 2024 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment of ...
SANTA CLARA, Calif. - Shockwave Medical , Inc. (NASDAQ: NASDAQ:SWAV) announced today that recent data from the REDUCER-I trial presented at the American College of Cardiology's 73rd Annual Scientific ...
Photo Credit: Adapted from Verheye S. The coronary sinus reducer. Presented at: TCT 2023. San Francisco, CA. An implantable coronary sinus reducer (CSR)—Shockwave Reducer (Shockwave Medical)—likely ...
(MENAFN- GlobeNewsWire - Nasdaq) Six-Month Results from REDUCER-I Trial Add to Positive Evidence of the Coronary Sinus Reducer to Treat Refractory Angina SANTA CLARA, Calif., April 08, 2024 (GLOBE ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results